Cytokines, growth, and environment factors in bone marrow plasma of acute lymphoblastic leukemia pediatric patients

European Cytokine Network

Volumn 25, Issue 1, 2014, Pages 8-13

  Kováč, Martin ^a   Vášková, Martina ^a   Petráčková, Denisa ^b   Pelková, Vendula ^a   Mejstříková, Ester ^a   Kalina, Tomáš ^a   Žaliová, Markéta ^a   Weiser, Jaroslav ^b   Starý, Jan ^a   Hrušák, Ondřej ^a  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

Bone marrow plasma; Cytokine antibody array; Pediatric acute lymphoblastic leukemia

Indexed keywords

ANGIOGENIN; CCL1 CHEMOKINE; CXCL1 CHEMOKINE; CXCL13 CHEMOKINE; CYTOKINE; FIBROBLAST GROWTH FACTOR 4; GROWTH FACTOR; HERPESVIRUS ENTRY MEDIATOR LIGAND; INTERLEUKIN 12; INTERLEUKIN 1B; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; LEUKEMIA INHIBITORY FACTOR; MACROPHAGE INFLAMMATORY PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1 GAMMA; MESSENGER RNA; MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; LIF PROTEIN, HUMAN; TIMP1 PROTEIN, HUMAN; TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW; CELL SURVIVAL; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE ANTIBODY ARRAY; ENVIRONMENTAL FACTOR; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; PLASMA; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; BIOSYNTHESIS; BLOOD; METABOLISM; PATHOLOGY;

BONE MARROW; CELL SURVIVAL; CHILD; CYTOKINES; HUMANS; LEUKEMIA INHIBITORY FACTOR; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN ARRAY ANALYSIS; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TUMOR MARKERS, BIOLOGICAL;

EID: 84904498299     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: 10.1684/ecn.2014.0348     Document Type: Article

References (31)

1. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030.
2. Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, Carroll AJ, Heerema NA, Rubnitz JE, Loh ML, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Gaynon PS, Camitta BM. Riskand response-based classification of childhood b-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the pediatric oncology group (pog) and children's cancer group (ccg). Blood 2007; 109: 926.
3. Zelent A, GreavesM, Enver T. Role of the tel-aml1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene 2004; 23: 4275.
4. Ito C, Kumagai M, Manabe A, Coustan-Smith E, Raimondi SC, Behm FG, Murti KG, Rubnitz JE, Pui CH, Campana D. Hyperdiploid acute lymphoblastic leukemia with 51 to 65 chromosomes:Adistinct biological entity with a marked propensity to undergo apoptosis. Blood 1999; 93: 315.
5. Nishii K, Katayama N, Miwa H, Shikami M, Masuya M, Shiku H, Kita K. Survival of human leukaemic b-cell precursors is supported by stromal cells and cytokines: Association with the expression of bcl-2 protein. Brit J Haematol 1999; 105: 701.
6. Nishigaki H, Ito C, Manabe A, Kumagai M, Coustan-Smith E, Yanishevski Y, Behm FG, Raimondi SC, Pui CH, Campana D. Prevalence and growth characteristics of malignant stem cells in b-lineage acute lymphoblastic leukemia. Blood 1997; 89: 3735.
7. Iversen PO, Wiig H. Tumor necrosis factor alpha and adiponectin in bone marrow interstitial fluid from patients with acute myeloid leukemia inhibit normal hematopoiesis. Clin Cancer Res 2005; 11: 6793.
8. Fronkova E, Mejstrikova E, Avigad S, Chik KW, Castillo L, Manor S, Reznickova L, Valova T, Zdrahalova K, Hrusak O, Jabali Y, Schrappe M, Conter V, Izraeli S, Li CK, Stark B, Stary J, Trka J. Minimal residual disease (mrd) analysis in the non-mrd-based all ic-bfm 2002 protocol for childhood all: Is it possible to avoid mrd testing? Leukemia 2008; 22: 989.
9. Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK, Liu HC, Mahfouz R, Raimondi SC, Lenny N, Patel A, Downing JR. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 2003; 102: 2951.
10. van Zelm MC, van der BurgM, de Ridder D, Barendregt BH, de Haas EF, Reinders MJ, Lankester AC, Revesz T, Staal FJ, van Dongen JJ. Ig gene rearrangement steps are initiated in early human precursor b cell subsets and correlate with specific transcription factor expression. J Immunol 2005; 175: 5912.
11. Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, Zhang J, Soden R, Hayakawa M, Kreiman G, Cooke MP, Walker JR, Hogenesch JB. A gene atlas of the mouse and human proteinencoding transcriptomes. Proc Natl Acad Sci U S A 2004; 101: 6062.
12. Ashley DM, Bol SJ, Kannourakis G. Viable bone marrow stromal cells are required for the in vitro survival of b-cell precursor acute lymphoblastic leukemic cells. Leukemia Res 1995; 19: 113.
13. Kumagai M, Manabe A, Pui CH, Behm FG, Raimondi SC, Hancock ML, Mahmoud H, Crist WM, Campana D. Stroma-supported culture in childhood b-lineage acute lymphoblastic leukemia cells predicts treatment outcome. J Clin Invest 1996; 97: 755.
14. Gibson LF. Survival of b lineage leukemic cells: Signals from the bone marrow microenvironment. Leuk Lymphoma 2002; 43: 19.
15. Kelley KW, Arkins S, Minshall C, Liu Q, Dantzer R. Growth hormone, growth factors and hematopoiesis. Horm Res 1996; 45: 38.
16. Ayala F, Dewar R, Kieran M, Kalluri R. Contribution of bone microenvironment to leukemogenesis and leukemia progression. Leukemia 2009; 23: 2233.
17. Wang P, Ruan LH and Zhao XQ. [expression of angiogenin-2 and vegf in acute leukemia and its significance]. Zhongguo shi yan xue ye xue za zhi /Zhongguo bing li sheng li xue hui = J Exp Hematol/Chin Ass Pathophysiol 2010; 18: 11.
18. Brunner B, Gunsilius E, Schumacher P, Zwierzina H, Gastl G, Stauder R. Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Hematother Stem Cell Res 2002; 11: 119.
19. Kittang AO, Hatfield K, Sand K, Reikvam H, Bruserud O. The chemokine network in acute myelogenous leukemia: Molecular mechanisms involved in leukemogenesis and therapeutic implications. Curr Top Microbiol Immunol 2010; 341: 149.
20. Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT. Expression of b-cell-attracting chemokine 1 (cxcl13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 2003; 101: 815.
21. Wang JM, Deng X, Gong W, Su S. Chemokines and their role in tumor growth and metastasis. J Immunol Methods 1998; 220: 1.
22. Burgess M, Cheung C, Chambers L, Ravindranath K, Minhas G, Knop L, Mollee P, McMillan NA, Gill D. Ccl2 and cxcl2 enhance survival of primary chronic lymphocytic leukemia cells in vitro. Leuk Lymphoma 2012; 53: 1988.
23. Matsumura I, Ikeda H, Kanakura Y. The effects of thrombopoietin on the growth of acute myeloblastic leukemia cells. Leuk Lymphoma 1996; 23: 533.
24. Zhang XL, Komada Y, Chipeta J, Li QS, Inaba H, Azuma E, Yamamoto H, Sakurai M. Intracellular cytokine profile of t cells from children with acute lymphoblastic leukemia. Cancer Immunol Immunother 2000; 49: 165.
25. Peled A, Lee BC, Sternberg D, Toledo J, Aracil M, Zipori D. Interactions between leukemia cells and bone marrow stromal cells: Stroma-supported growth vs. Serum dependence and the roles of tgf-beta and m-csf. Exp Hematol 1996; 24: 728.
26. Metcalf D. The leukemia inhibitory factor (lif). Int J Cell Cloning 1991; 9: 95.
27. Metcalf D. The unsolved enigmas of leukemia inhibitory factor. Stem Cells 2003; 21: 5.
28. Murate T, Hayakawa T. Multiple functions of tissue inhibitors of metalloproteinases (timps): New aspects in hematopoiesis. Platelets 1999; 10: 5.
29. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A. Cell growthpromoting activity of tissue inhibitor of metalloproteinases-2 (timp-2). J Cell Sci 1994; 107(Pt 9): 2373.
30. Stetler-Stevenson WG, Bersch N, Golde DW. Tissue inhibitor of metalloproteinase-2 (timp-2) has erythroid-potentiating activity. FEBS letters 1992; 296: 231.
31. Guedez L, Courtemanch L, Stetler-Stevenson M. Tissue inhibitor of metalloproteinase (timp)-1 induces differentiation and an antiapoptotic phenotype in germinal center b cells. Blood 1998; 92: 1342.